Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 7.0%

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 4,280,000 shares, an increase of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the short-interest ratio is presently 18.6 days.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target for the company. Finally, Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, INmune Bio has an average rating of “Buy” and a consensus target price of $20.75.

INmune Bio Trading Down 3.9 %

NASDAQ INMB opened at $9.76 on Tuesday. The stock has a market cap of $216.40 million, a P/E ratio of -4.48 and a beta of 1.78. INmune Bio has a 52 week low of $4.32 and a 52 week high of $14.74. The company’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $6.04.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently bought and sold shares of INMB. Barclays PLC boosted its position in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after purchasing an additional 24,906 shares in the last quarter. Jane Street Group LLC bought a new position in shares of INmune Bio during the 3rd quarter valued at about $79,000. Geode Capital Management LLC boosted its position in shares of INmune Bio by 6.6% during the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock valued at $1,857,000 after purchasing an additional 21,262 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of INmune Bio during the 3rd quarter valued at about $113,000. Finally, State Street Corp boosted its position in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after purchasing an additional 58,838 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.